Rekowski Jan, Köllmann Claudia, Bornkamp Björn, Ickstadt Katja, Scherag André
a Institute for Medical Informatics, Biometry and Epidemiology , University of Duisburg-Essen , Germany.
b Faculty of Statistics , TU Dortmund , Germany.
J Biopharm Stat. 2017;27(5):885-901. doi: 10.1080/10543406.2017.1293078. Epub 2017 Mar 31.
Phase II trials are intended to provide information about the dose-response relationship and to support the choice of doses for a pivotal phase III trial. Recently, new analysis methods have been proposed to address these objectives, and guidance is needed to select the most appropriate analysis method in specific situations. We set up a simulation study to evaluate multiple performance measures of one traditional and three more recent dose-finding approaches under four design options and illustrate the investigated analysis methods with an example from clinical practice. Our results reveal no general recommendation for a particular analysis method across all design options and performance measures. However, we also demonstrate that the new analysis methods are worth the effort compared to the traditional ANOVA-based approach.